FBXO4 and esophageal squamous cell carcinoma: Furthermore, studies have demonstrated that combination therapies can overcome resistance to the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor palbociclib in esophageal squamous cell carcinoma (ESCC) with dysregulation of the FBXO4-cyclin D1 axis (105).